Moderna’s experimental vaccine prevents cancer recurrence, in ‘historic’ win for personalized medicine. Its stock soared.

BREAKING: Moderna and Merck's experimental mRNA cancer vaccine prevents melanoma recurrence in a late-stage trial, hailed as a 'historic' win for personalized medicine, sending $MRNA soaring.

An mRNA vaccine just stopped melanoma from coming back. In a late-stage trial.

Moderna and Merck have been building this thing for years, a personalized cancer vaccine, custom made from each patient's own tumor. Tonight they're calling the result historic, and honestly, for once the word fits. This is the technology that made COVID shots, now pointed at cancer, and it worked in the trial phase that actually matters for approval.

Wall Street noticed immediately. Moderna stock soared on the news, and you'd expect it to, because this is the future the company has been promising since the pandemic money dried up.

But step back from the ticker for a second. Melanoma is one of the deadliest skin cancers there is, and recurrence is the fear every survivor lives with. If this holds up through regulators, we're talking about teaching a patient's own immune system to remember their cancer and kill it on sight.

Medicine doesn't get many nights like this one.

This is Sara White, reporting for HIT.

Source Read the original reporting at marketwatch.com